Chemomab Therapeutics (NASDAQ:CMMB) announced its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.21, Yahoo Finance reports.
Chemomab Therapeutics stock traded up $0.41 during mid-day trading on Friday, hitting $17.00. 144,693 shares of the company were exchanged, compared to its average volume of 215,518. The business has a fifty day moving average of $30.48. Chemomab Therapeutics has a 1-year low of $12.32 and a 1-year high of $168.80.
A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Chemomab Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Oppenheimer initiated coverage on Chemomab Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $42.00 price objective on the stock.
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.